An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis

Neurology

Volumn 71, Issue 6, 2008, Pages 400-406

  Sanders, D B ^a   Hart, I K ^b   Mantegazza, R ^c   Shukla, S S ^d   Siddiqi, Z A ^e   De Baets, M H V ^f   Melms, A ^g   Nicolle, M W ^h   Solomons, N ⁱ   Richman, D P ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d Aspreva Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

ⁱ Aspreva Pharmaceuticals Corporation   (Canada)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CHRONIC BRONCHITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LIMB PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYASTHENIA GRAVIS; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PLACEBO EFFECT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SHORT FORM 36; SIALOADENITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; COMPARATIVE STUDY; IMMUNOLOGY; INTERNATIONAL COOPERATION; MIDDLE AGED;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; PREDNISONE; PROSPECTIVE STUDIES;

EID: 44249093570     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000312374.95186.cc     Document Type: Article

References (28)

1. Fonseca V, Havard CW. The natural course of myasthenia gravis. BMJ 1990;300:1409-1410.
2. Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 2005;14(suppl 1):46-49.
3. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-699.
4. Rozsa C, Lovas G, Fornadi L, Szabo G, Komoly S. Safety of long-term combined immunosuppressive treatment in myasthenia gravis: analysis of adverse effects of 163 patients. Eur J Neurol 2006;13:947-952.
5. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-913.
6. Caponnetto C, Rossi E, Primavera A. Mycophenolate mofetil: a new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection. Eur Neurol 2001;46:53-54.
7. Kotani A, Takahashi A, Koga H, et al. Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells. Eur J Haematol 2002;69:318-320.
8. Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000;23:1287-1289.
9. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122.
10. Prakash KM, Ratnagopal P, Puvanendran K, Lo YL. Mycophenolate mofetil as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience. J Clin Neurosci 2007;14:278-281.
11. Schneider C, Gold R, Reiners K, Toyka KV. Mycopheno-late mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001;46:79-82.
12. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99.
13. Gogovska L, Ljapcev R. An open-label, 12-month trial of mycophenolate mofetil in myasthenia gravis. Eur J Neurol 2004;11(suppl 2):273.
14. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96.
15. Cos L, Mankodi AK, Tawil R, Thornton CA. Mycophe-nolate mofetil is safe and well-tolerated in myasthenia gravis. Neurology 2000;54(suppl 3):A137.
16. Dolezil D, Zapletalova O. Treatment of myasthenia gravis with mycophenolate mofetil: our experience. Eur J Neurol 2004;11(suppl 2):274.
17. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycopheno-late mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438-1440.
18. Meriggioli MN, Rowin J. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol 2003;20: 382-385.
19. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Myco-phenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003; 998:494-499.
20. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007;4:CD005224.
21. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005;2:CD002828.
22. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
23. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myas-thenia gravis score. Ann NY Acad Sci 1998;841:769-772.
24. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.
25. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-1783.
26. US Food and Drug Administration. Mycophenolate mofetil (CellCept®) labelling. Available at: http://www.fda.gov/cder/foi/label/2000/50759S51b1.pdf.
27. van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001;51:601-607.
28. Behrend M. Adverse gastrointestinal effects of mycophe-nolate mofetil: aetiology, incidence and management. Drug Saf 2001;24:645-663.